Suppr超能文献

神经纤维瘤病 1 型的肿瘤和全身序列分析。

Tumor and Constitutional Sequencing for Neurofibromatosis Type 1.

机构信息

Division of Hematology/Oncology, Pediatrics, Benioff Children's Hospital Oakland, University of California San Francisco, San Francisco, CA.

Department of Pathology, University of California San Francisco, San Francisco, CA.

出版信息

JCO Precis Oncol. 2022 May;6:e2100540. doi: 10.1200/PO.21.00540.

Abstract

PURPOSE

variants in tumors are important to recognize, as multiple mechanisms may give rise to biallelic variants. Both deletions and copy-neutral loss of heterozygosity (LOH) are potential mechanisms of loss, distinct from point mutations, and additional genes altered may drive different tumor types. This study investigates whether tumors from individuals with neurofibromatosis type 1 (NF1) demonstrate additional gene variants and detects second hits using paired germline and somatic sequencing. In addition, rare tumor types in NF1 may also be characterized by tumor sequencing.

MATERIALS AND METHODS

Sequences of 529 cancer driver genes were analyzed in 6,381 tumors, yielding 391 -mutated tumors in which LOH analysis was performed. Driver genes were evaluated by tumor type including malignant peripheral nerve sheath tumors and gliomas.

RESULTS

LOH was seen in 133 of 391 tumor samples in the cohort. Individuals with NF1 had more prevalent copy-neutral LOH ( < .0001), suggesting somatic intrachromosomal recombination. Osteosarcoma in NF1 also had LOH and additional p53 alteration. second hit data from tumors were informative for inferring deleteriousness of missense variants that were conflicting in ClinVar, potentially helping to add to annotation. Although criteria for evaluating germline and somatic variants are different, deleterious effects on function may be shared.

CONCLUSION

Sequencing of NF1-associated tumors demonstrated a spectrum of second hits in and the prevalence of copy-neutral LOH. Future work may be aimed at further understanding of LOH mechanisms and strategies to mitigate tumor risk.

摘要

目的

识别肿瘤中的变异很重要,因为多种机制可能导致双等位基因变异。缺失和等位基因杂合性丢失(LOH)均为潜在的缺失机制,与点突变不同,并且可能导致不同肿瘤类型的其他基因改变。本研究调查是否 NF1 个体的肿瘤表现出额外的基因变异,并使用配对的种系和体细胞测序检测第二击。此外,NF1 中的罕见肿瘤类型也可能通过肿瘤测序来表征。

材料和方法

分析了 529 个癌症驱动基因在 6381 个肿瘤中的序列,其中 391 个肿瘤发生了突变,并对 LOH 分析进行了分析。根据肿瘤类型评估了驱动基因,包括恶性外周神经鞘瘤和神经胶质瘤。

结果

在队列中的 391 个肿瘤样本中,有 133 个存在 LOH。NF1 个体中更常见的是无拷贝中性 LOH(<0.0001),提示体细胞染色体内重组。NF1 中的骨肉瘤也存在 LOH 和其他 p53 改变。肿瘤的第二击数据有助于推断 ClinVar 中存在冲突的错义变异的有害性,可能有助于增加注释。尽管评估种系和体细胞变异的标准不同,但对功能的有害影响可能是共享的。

结论

NF1 相关肿瘤的测序显示了 中的第二击谱和无拷贝中性 LOH 的普遍性。未来的工作可能旨在进一步了解 LOH 机制和减轻肿瘤风险的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d377/9200388/5fcae04af560/po-6-e2100540-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验